Financial PerformanceDynavax has a strong cash position with $764.0M in cash, cash equivalents, and marketable securities, indicating financial health and liquidity.
Market OpportunityThe upgraded U.S. ACIP recommendation for Hepatitis B tripled the eligible population, increasing to 130 million eligible patients, thereby expanding the market opportunity for Heplisav-B.
Market Share And GrowthHeplisav-B is the only two-dose adult Hepatitis B vaccine available, providing a unique market position for Dynavax.